In a clinical trial published this week in PLoS Medicine, Charles Sawyers and colleagues looked at the safety of a drug called rapamycin in a selected group of patients who were undergoing surgery after recurrence of glioblastoma (a highly malignant tumor of the brain).
In a related research in translation article about the implications of the research, Robert J. Weil, who was not involved in the trial, suggests that the study points the way "toward rational design of therapy for stratified groups of patients who share common molecular features" and a future that allows "cancer researchers and clinicians to reach toward the holy grail of individualized therapy"
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. (2008)
"Antitumor activity of rapamycin in patients with recurrent PTEN-deficient glioblastoma."
PLoS Med 5(1): e8
Click here to view article online.
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues.
PLoS Medicine
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource.
Public Library of Science
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment